FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
Sermorelin + GHRP-6 + GHRP-2 combines complementary upstream signals within the growth hormone axis. Sermorelin activates GH synthesis through the GHRH receptor, while GHRP-6 and GHRP-2 stimulate the ghrelin receptor GHS-R1a to amplify GH pulse release. Together, they enhance endogenous, pulsatile growth hormone signaling through dual-pathway stimulation, along with some gastric ghrelin effects.
Sermorelin is a synthetic 29-amino acid fragment of growth hormone–releasing hormone [1]. It represents the shortest, completely functional portion of the endogenous GHRH. Sermorelin works via upstream mechanisms rather than supplying growth hormone directly [1]. It acts through the GHRH receptor on somatotroph cells in the anterior pituitary to increase growth hormone synthesis and pulsatile secretion [2].
Sermorelin remains under normal physiologic regulation through negative feedback from somatostatin, which helps modulate growth hormone output and preserve its natural pulsatile release pattern [2]. In addition to stimulating secretion, sermorelin also supports transcription of the growth hormone gene, helping to maintain the integrity of the growth hormone neuroendocrine axis [3]. Because it stimulates endogenous growth hormone production rather than replacing growth hormone directly, sermorelin is considered a more physiologic approach to enhancing growth hormone signalling [3].
Growth hormone–releasing peptide-2 (GHRP-2), is a synthetic hexapeptide that functions as a growth hormone secretagogue [4]. It agonises ghrelin receptor GHS-R1a, a G-protein-coupled receptor expressed in the hypothalamus and anterior pituitary [4]. When GHRP-2 binds GHS-R1a, intracellular signalling pathways activate, increasing calcium flux and downstream second-messenger activity to stimulate pulsatile growth hormone release from pituitary somatotroph cells [5].
GHS-R1a receptor activation also increases the amplitude of growth hormone pulses and can raise circulating Insulin-like Growth Factor (IGF-1) [6]. In addition to growth hormone, GHRP-2 may stimulate adrenocorticotropic hormone (ACTH), suggesting broader HPA-axis engagement [7]. Because it works via receptor-mediated stimulation rather than direct hormone replacement, GHRP-2 is widely used in research and in diagnostics to assess growth hormone reserve [8]. Its unique pharmacologic profile makes it a tool for studying ghrelin receptor signalling, endocrine feedback regulation, and somatotrophic axis dynamics [7].
Growth hormone–releasing peptide-6 (GHRP-6) is a synthetic hexapeptide that also functions as a growth hormone secretagogue [9]. Like GHRP-2, GHRP-6 acts as an agonist of the G-protein-coupled ghrelin receptor GHS-R1a, expressed in the hypothalamus and anterior pituitary [9]. This binding mimics the action of endogenous ghrelin and stimulates intracellular signalling cascades that increase calcium mobilization and promote pulsatile growth hormone release from pituitary somatotroph cells [10]. This mechanism enhances both the amplitude and frequency of growth hormone pulses [10].
The effects of GHRP-6 appear to be influenced by metabolic context, with insulin augmenting the growth hormone response, while concurrent carbohydrate or lipid intake can blunt it [11]. Interestingly, GHRP-6 is one of the only GHRPs that can actively increase hunger and food intake. Because it stimulates endogenous growth hormone release via receptor activation rather than direct hormone administration, GHRP-6 is primarily used in research contexts to study ghrelin signalling, somatotropic regulation, and downstream metabolic effects [11].
The combination of sermorelin with growth hormone–releasing peptides produce complementary effects through stimulation of growth hormone release via two unique upstream receptors that converge on the same pituitary somatotroph output [12]. Sermorelin activates the GHRH receptor to promote growth hormone synthesis and physiologic, pulsatile secretion [2]. Conversely, GHRP-2 and GHRP-6 act as ghrelin receptor agonists, which increase intracellular signalling and calcium-dependent pathways that also drive pulsatile growth hormone release [5,10]. Pairing a GHRH-pathway signal from sermorelin with a ghrelin pathway signal from GHRPs may produce a stronger growth hormone pulse than either agent alone through stimulating the axis from two distinct areas rather than one.
There is some in vitro evidence to suggest that GHRP-2 and GHRP-6 each act synergistically with GHRH to stimulate growth hormone release, supporting the rationale for combining a GHRH analogue like sermorelin with a GHRP [12]. Equal dosing in this formulation is designed to provide a balanced stimulation across both regulatory arms of the somatotropic axis to support a coordinated GH pulse rather than disproportionally driving one pathway.
References:
1 Prakash, A. and Goa, K. L. (1999) Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, Springer Nature 12, 139–157
2 Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D. and von Haehling, S. (2020) Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, Wiley 3, 25–37
3 Walker, R. F. (2006) Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin. Interv. Aging, Dove Medical Press Ltd. 1, 307–308
4 Moulin, A., Brunel, L., Verdie, P., Gavara, L., Martinez, J. and Fehrentz, J.-A. (2014) Ghrelin Receptor Ligands: Design and Synthesis of Pseudopeptides and Peptidomimetics. Curr. Chem. Biol., Bentham Science Publishers Ltd. 7, 254–270
5 &na; (2004) Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R. D., Springer Nature 5, 236–239
6 Furuta, S., Shimada, O., Doi, N., Ukai, K., Nakagawa, T., Watanabe, J., et al. (2004) General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung, Georg Thieme Verlag KG 54, 868–880
7 Kimura, T., Shimatsu, A., Arimura, H., Mori, H., Tokitou, A., Fukudome, M., et al. (2010) Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2. Endocr. J., Japan Endocrine Society 57, 639–644
8 McDowell, R. S., Elias, K. A., Stanley, M. S., Burdick, D. J., Burnier, J. P., Chan, K. S., et al. (1995) Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc. Natl. Acad. Sci. U. S. A., Proceedings of the National Academy of Sciences 92, 11165–11169
9 Camanni, F., Ghigo, E. and Arvat, E. (1998) Growth hormone-releasing peptides and their analogs. Front. Neuroendocrinol., Elsevier BV 19, 47–72
10 McGirr, R., McFarland, M. S., McTavish, J., Luyt, L. G. and Dhanvantari, S. (2011) Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a. Regul. Pept., Elsevier BV 172, 69–76
11 Peñalva, A., Carballo, A., Pombo, M., Casanueva, F. F. and Dieguez, C. (1993) Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. J. Clin. Endocrinol. Metab., The Endocrine Society 76, 168–171
12 Cheng, J., Wu, T. J., Butler, B. and Cheng, K. (1997) Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci., Elsevier BV 60, 1385–1392
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Sermorelin + GHRP-6 + GHRP-2 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
